Astrid Van den Branden

Ms. Astrid Van den Branden

University of Antwerp, Faculty of Biomedical Sciences, Laboratory of Pathophysiology
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GBGeoffrey Van den Bergh
Geoffrey Van den Bergh
SMSofie De Moudt
Sofie De Moudt
Astrid Van den BrandenAstrid Van den Branden
Astrid Van den Branden
ENEllen Neven
Ellen Neven
HLHanne Leysen
Hanne Leysen
AVAnja Verhulst
Anja Verhulst
Arterial media calcification (AMC) is predominantly regulated by vascular smooth muscle cells (VSMCs), which transdifferentiate into pro-calcifying cells. In contrast, there is little evidence for endothelial cells playing a role in the disease. The current study investigates cellular functioning and molecular pathways underlying AMC, respectively by, an ex vivo isometric organ bath set-up to explore the interaction between VSMCs and ECs and quantitative proteomics followed by functional pathway interpretation. AMC development, which was induced in mice by dietary warfarin administration, was proved by positive Von Kossa staining and a significantly increased calcium content in the aorta compared to that of control mice. The ex vivo organ bath set-up showed calcified aortic segments to be significantly more sensitive to phenylephrine induced contraction, compared to control segments. This, together with the fact that calcified segments as compared to control segments, showed a significantly smaller contraction in the absence of extracellular calcium, argues for a reduced basal NO production in the calcified segments. Moreover, proteomic data revealed a reduced eNOS activation to be part of the vascular calcification process. In summary, this study identifies a poor endothelial function, next to classic pro-calcifying stimuli, as a possible initiator of arterial calcification.

15 April 2022 in The FASEB Journal
Verified
Journal Article
Open access
GBGeoffrey Van Den Bergh
Geoffrey Van Den Bergh
Astrid Van den BrandenAstrid Van den Branden
Astrid Van den Branden
BOBritt Opdebeeck
Britt Opdebeeck
PFPaul Fransen
Paul Fransen
ENEllen Neven
Ellen Neven
AVAnja Verhulst
Anja Verhulst
Arterial media calcification is an active cell process. This encompasses osteochondrogenic transdifferentiation of vascular smooth muscle cells followed by the deposition of calcium‐phosphate crystals. Increasing evidence suggests a significant role for endothelial cells (ECs) in the development of arterial media calcification. This manuscript explores a role for endothelial dysfunction in the disease progression of arterial media calcification. Male rats were randomly assigned to four different groups. The first group received standard chow. The second group was given L‐NAME (≈50 mg kg −1 · d −1 ), to induce endothelial dysfunction, in addition to standard chow. The third group and fourth group received a warfarin‐supplemented diet to induce mild calcification and the latter group was co‐administered L‐NAME. Prior to sacrifice, non‐invasive measurement of aortic distensibility was performed. Animals were sacrificed after 6 weeks. Arterial media calcification was quantified by measuring aortic calcium and visualized on paraffin‐embedded slices by the Von Kossa method. Arterial stiffness and aortic reactivity was assessed on isolated carotid segments using specialized organ chamber setups. Warfarin administration induced mineralization. Simultaneous administration of warfarin and L‐NAME aggravated the arterial media calcification process. Through organ chamber experiments an increased vessel tonus was found, which could be linked to reduced basal NO availability, in arteries of warfarin‐treated animals. Furthermore, increased calcification because of L‐NAME administration was related to a further compromised endothelial function (next to deteriorated basal NO release also deteriorated stimulated NO release). Our findings suggest early EC changes to impact the disease progression of arterial media calcification.

5 April 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
Astrid Van den BrandenAstrid Van den Branden
Astrid Van den Branden
AVAnja Verhulst
Anja Verhulst
Patrick D'haesePatrick D'haese
Patrick D'haese
BOBritt Opdebeeck
Britt Opdebeeck
The presence of arterial media calcification, a highly complex and multifactorial disease, puts patients at high risk for developing serious cardiovascular consequences and mortality. Despite the numerous insights into the mechanisms underlying this pathological mineralization process, there is still a lack of effective treatment therapies interfering with the calcification process in the vessel wall. Current anti-calcifying therapeutics may induce detrimental side effects at the level of the bone, as arterial media calcification is regulated in a molecular and cellular similar way as physiological bone mineralization. This especially is a complication in patients with chronic kidney disease and diabetes, who are the prime targets of this pathology, as they already suffer from a disturbed mineral and bone metabolism. This review outlines recent treatment strategies tackling arterial calcification, underlining their potential to influence the bone mineralization process, including targeting vascular cell transdifferentiation, calcification inhibitors and stimulators, vascular smooth muscle cell (VSMC) death and oxidative stress: are they a friend or foe? Furthermore, this review highlights nutritional additives and a targeted, local approach as alternative strategies to combat arterial media calcification. Paving a way for the development of effective and more precise therapeutic approaches without inducing osseous side effects is crucial for this highly prevalent and mortal disease.

15 December 2022 in The FASEB Journal
Verified
Journal Article
Closed access
BOBritt Opdebeeck
Britt Opdebeeck
IHIne Huysmans
Ine Huysmans
Astrid Van den BrandenAstrid Van den Branden
Astrid Van den Branden
IOIsabel R. Orriss
Isabel R. Orriss
PDPatrick C. D'HAese
Patrick C. D'HAese
AVAnja Verhulst
Anja Verhulst

22 April 2024 in JBMR Plus
Verified
Journal Article
Open access
PDF file
BOBritt Opdebeeck
Britt Opdebeeck
Astrid Van den BrandenAstrid Van den Branden
Astrid Van den Branden
SASaar Adriaensen
Saar Adriaensen
IOIsabel R Orriss
Isabel R Orriss
JPJessal J Patel
Jessal J Patel
AVAnja Verhulst
Anja Verhulst
Arterial media calcification or pathological deposition of calcium-phosphate crystals in the vessel wall contributes significantly to the high mortality rate observed in patients with CKD. Extracellular nucleotides (ie, ATP or UTP) regulate the arterial calcification process by interacting with (1) purinergic receptors and (2) breakdown via ecto-nucleotidases, such as ectonucleotide pyrophosphatase/phosphodiesterase NPP1 or NPP3, affecting the local levels of calcification inhibitor, pyrophosphate, and stimulator inorganic phosphate (PPi/Pi ratio). Also, it has been shown that ATP analogs (ie, β,γ-methylene-ATP [β,γ-meATP]) inhibit vascular smooth muscle cell calcification in vitro. In the first experiment, daily dosing of β,γ-meATP (2 mg/kg) was investigated in rats fed a warfarin diet to trigger the development of non–CKD-related arterial medial calcifications. This study showed that β,γ-meATP significantly lowered the calcium scores in the aorta and peripheral vessels in warfarin-exposed rats. In a second experiment, daily dosing of 4 mg/kg β,γ-meATP and its metabolite medronic acid (MDP) was analyzed in rats fed an adenine diet to promote the development of CKD-related arterial medial calcification. Administration of β,γ-meATP and MDP did not significantly decrease aortic calcification scores in this model. Moreover, both compounds induced deleterious effects on physiological bone mineralization, causing an imminent risk for worsening the already compromised bone status in CKD. Due to this, it was not possible to raise the dosage of both compounds to tackle CKD-related arterial calcification. Again, this points out the difficult task of targeting solely ectopic calcifications without negatively affecting physiological bone mineralization. On the other hand, aortic mRNA expression of Enpp1 and Enpp3 was significantly and positively associated with aortic calcification scores, suggesting that normalizing the aortic NPP1/3 activity to control values might be a possible target to treat (CKD-induced) arterial media calcifications. The deposition of calcium-phosphate crystals in the arteries, also called arterial calcification, has a serious impact on the mortality in patients with chronic renal failure. We have investigated the therapeutic efficiency and safety of the drug β,γ-meATP on arterial calcification in rats. In a first experiment, rats were exposed to high, toxic dosages of warfarin, an anticoagulant, to induce arterial calcification without affecting the kidney function. The drug β,γ-meATP was able to prevent the development of mild arterial calcifications in rats exposed to warfarin. In a second experiment, rats were fed an adenine diet to trigger chronic renal failure, which leads to the development of severe arterial calcifications. Unfortunately, the drug β,γ-meATP and its metabolite medronic acid did not significantly reduce the presence of severe arterial calcifications in rats with chronic renal failure. Moreover, these compounds induced side-effects at the level of the bones, causing an imminent risk for worsening the already compromised bone status in chronic renal failure. Due to this, it was not possible to raise the dosage of both compounds to tackle arterial calcification in a chronic kidney failure setting. Again, this points out the difficult task of targeting solely arterial calcifications without negatively affecting physiological bone mineralization.

29 November 2024 in The Journal of Pathology
Verified
Journal Article
Open access
Astrid Van den BrandenAstrid Van den Branden
Astrid Van den Branden
BOBritt Opdebeeck
Britt Opdebeeck
SASaar Adriaensen
Saar Adriaensen
PEPieter Evenepoel
Pieter Evenepoel
TBTom Vanden Berghe
Tom Vanden Berghe
AVAnja Verhulst
Anja Verhulst
Arterial media calcification is a severe cardiovascular complication commonly manifesting in patients with chronic kidney disease (CKD). Patients with CKD frequently undergo intravenous iron therapy to address iron deficiency. Iron is suggested to be sequestered in vascular cells, potentially leading to oxidative (lipid) stress and cell death, which are recognized as key contributors to arterial calcification. The objective of this study was to investigate the effect of intravenous iron administration on CKD‐induced arterial media calcification. Therefore, adenine‐induced CKD rats were treated intravenously with iron and checked for arterial iron deposition and calcification, as well as for ferritin and lipid peroxidation markers. Additionally, arterial sections from patients with CKD who were dialysis dependent were analyzed for these parameters. This study showed that intravenous iron administration in CKD rats led to arterial iron deposition and a lipid peroxidation signature. CKD‐induced arterial calcification was increased upon iron treatment and correlated with arterial iron accumulation and lipid peroxidation markers. Patients with CKD who were dialysis dependent showed arterial iron accumulation and elevated lipid peroxidation, but a direct correlation with arterial calcification was lacking. Taken together, iron treatment is suggested as a potential contributor to the calcification process, instead of being a predominant factor, thereby emphasizing the complexity of arterial calcification as a multifactorial disease. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.